Medicus Pharma Ltd. Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

Key Points from the Report

• Nasdaq Notification: On April 21, 2026, Medicus Pharma Ltd. received a written notice from the Nasdaq Stock Market LLC indicating the company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
• Bid Price Issue: The closing bid price for Medicus Pharma’s shares was below \$1.00 per share for the previous 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2).
• No Immediate Impact: The notice does not immediately affect the listing or trading of Medicus Pharma’s shares on the Nasdaq Capital Market.
• Compliance Timeline: The company has 180 calendar days, until October 19, 2026, to regain compliance by having its shares close at or above \$1.00 per share for at least ten consecutive business days during this period.
• Second Compliance Period: If compliance is not achieved by the initial deadline, Medicus Pharma may be eligible for a second 180-day compliance period, subject to meeting Nasdaq’s standards.
• Delisting Risk: Failure to regain compliance during the permitted period(s) will result in Nasdaq notifying the company of its intention to delist its shares. The company would then have the option to appeal this determination to a Nasdaq hearings panel.
• Company Response: Medicus Pharma intends to actively monitor the closing bid price and may implement strategies to regain compliance, such as potential share consolidation (reverse stock split) or other corporate actions.

Other Notable Disclosures

• Securities Registered:
  • Common shares, no par value (Trading symbol: MDCX)
  • Warrants, each exercisable for one common share at an exercise price of \$4.64 per share (Trading symbol: MDCXW)
  • Both securities are listed on the Nasdaq Capital Market.
• Emerging Growth Company: Medicus Pharma identifies as an emerging growth company under U.S. securities law, which may allow for certain reduced disclosure requirements and extended transition periods for new accounting standards.
• Material Agreements: The company also filed an amendment (Amendment No. 1) to its Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC, allowing for at-the-market offerings of up to \$50 million in common shares. The legal opinion supporting this registration was provided by Bennett Jones LLP.

Important Information for Shareholders and Investors

• Price Sensitive Developments:
  • The risk of potential delisting from Nasdaq is a significant event that could materially affect the liquidity and market value of Medicus Pharma’s shares.
  • Delisting could limit investor access, reduce trading volumes, and make it more difficult for the company to raise capital in the public markets.
  • The company’s intention to regain compliance may result in corporate actions such as a reverse stock split, which can have substantial share price effects.
• Forward-Looking Statements: The report contains forward-looking statements regarding the company’s intentions and strategies to regain compliance, as well as potential future sales of shares. Actual results may differ materially due to risks and uncertainties.

Summary for Investors

Medicus Pharma Ltd. faces a critical period after receiving a Nasdaq non-compliance notice regarding its share price. While there is no immediate threat to the company’s Nasdaq listing, investors should closely monitor developments, as failure to address the issue could lead to delisting. This would likely have a negative impact on share liquidity and value. The company’s management is exploring options to regain compliance and maintain its listing, but the outcome remains uncertain. Additionally, the company’s ongoing at-the-market equity program may result in share dilution. Investors are urged to review all SEC filings and stay updated on corporate actions in the coming months.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions. The information herein is based on filings and statements by Medicus Pharma Ltd. and may be subject to change. Forward-looking statements are inherently subject to risks and uncertainties.

View Medicus Pharma Ltd. Historical chart here